title: Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
authors.affiliation: Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, University of Perugia, Italy.
authors.forename: Niccolò
authors.initials: N
authors.lastname: Bolli
authors.forename: Mauro
authors.initials: M
authors.lastname: Di Ianni
authors.forename: Stefano
authors.initials: S
authors.lastname: Simonetti
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Cerroni
authors.forename: Arcangelo
authors.initials: A
authors.lastname: Liso
authors.forename: Brunangelo
authors.initials: B
authors.lastname: Falini
authors.forename: Antonio
authors.initials: A
authors.lastname: Tabilio
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009182:Mycosis Fungoides / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab